ported by experimental studies [6 ]. As a consequence, to have higher plasma PAI-1 levels, P=0.06, no differthe candidate genes investigated in association studies ence in allele frequency (4G/5G) was seen between have predominantly been cardiovascular risk factors, patients with and without nephropathy: 0.538/0.462 vs i.e. genes encoding components of the renin-angioten-0.539/0.461, respectively. Nor did ApoE allele sin system, genes of the fibrinolytic cascade and genes frequencies (e2/e3/e4) differ between nephropathic regulating lipid metabolism. and normoalbuminuric patients: 0.099/0.749/0.152 vs Plasminogen activator inhibitor-1 (PAI-1) plays a 0.081/0.745/0.174, respectively.
or if patients reported a history of either angina pectoris, in non-diabetic [23, 24] and type 2 diabetic populadefined in accordance to Rose [31] , or of myocardial tions [25] .
infarction according to WHO criteria [29] .
Therefore, the aim of this study was to investigate Arterial blood pressure was measured in the supine posithe relationship between the 4G/5G polymorphism of tion after 10 min rest using a Hawksley random zero sphygthe PAI-1 gene and the ApoE polymorphism on the momanometer and an appropriate cuff size. Diastolic blood one hand, and diabetic nephropathy on the other hand, pressure was recorded at the disappearance of Korotkoff in a group of type 1 diabetic patients. In addition, we sounds (phase V ). Retinopathy was assessed by fundus examined the association between these polymorph-photography after pupillary dilatation and graded: nil, simisms and CHD in nephropathic patients with type 1 plex or proliferative diabetic retinopathy. Smokers were defined as persons smoking more than one cigarette/ diabetes mellitus.
cigar/pipe a day, all others were classified as non-smokers. Urinary albumin concentration was measured by enzyme
Subjects and methods
immunoassay [32] from 24-h urine collections. Haemoglobin (Hb) A 1c was measured by HPLC (DIAMAT, Bio-Rad, CA, USA) (normal range 4.1-6.1%). Serum creatinine concentraDuring 1993, 198 type 1 diabetic patients with diabetic tion was assessed using a kinetic Jaffé method. Serum total nephropathy, whose glomerular filtration rate had been cholesterol and triglyceride concentrations were determined measured during the same year, were recruited from the enzymatically from a venous blood sample, and ApoA-1 and outpatient clinic at Steno Diabetes Center for a case-control B by endpoint turbidimetry. High-density lipoprotein study [26, 27] . Diabetic nephropathy was diagnosed clinically (HDL)-cholesterol was determined after precipitation of based on the following criteria: persistent albuminuria ApoB containing lipoprotein with phosphotungstic acid. >300 mg/24 h in at least two of three consecutive 24-h urine LDL-cholesterol was calculated using the Friedewald collections, presence of retinopathy, and no clinical or laborformula [33] . atory evidence of kidney or renal tract disease other than diabetic glomerulosclerosis [28] . A total of 192 patients with long-standing type 1 diabetes and persistent normoalbuminu-Statistical analysis ria, matched for sex, age and duration of diabetes, served as controls. Five women with nephropathy and six with nor-Normally distributed variables are given as means±SD. moalbuminuria received oestrogen therapy. None of the Urinary albumin excretion rate, serum creatinine, triglyceride patients was taking lipid-lowering drugs, whereas 13 and 3 and PAI-1 concentrations were log transformed before statistpatients had low-dose aspirin (75-150 mg daily) prescribed ical analysis, because of their positively skewed distribution, in the group with and without nephropathy, respectively. and given as medians (range) or geometric means (95% CI ). The study was approved by the local ethics committee, and Comparisons between groups were performed using an all patients gave their informed consent. unpaired Student's t-test or analysis of variance (ANOVA). All investigations were performed in the morning following Frequencies are given as percentage and 95% confidence an overnight fast-in an attempt to avoid diurnal variation. interval. A chi-square test was used to compare genotype Venous blood was drawn with minimal stasis from an and allele distributions in cases and controls, and was also antecubital vein into EDTA tubes. Centrifugation was per-used for comparison between groups of non-continuous formed within 1 h and plasma was stored at −80°C.
variables. Allele frequencies were estimated by the gene Lymphocytes were isolated from peripheral blood and counting method, and Hardy-Weinberg equilibrium was DNA was prepared using standard techniques. A polymerase checked by a chi-square test. A P-value (two-tailed ) <0.05 chain reaction (PCR) was used to detect the two alleles of was considered statistically significant. All calculations were the 4G/5G polymorphism and the three alleles of the restric-made using commercially available programs (Statgraphics, tion fragment length ApoE polymorphism. DNA was ampli-STSC, Rockville, MD, USA). fied and genotyped as described in the CANVAS Internet Site (http:ifr69.vjf.inserm.fr/~canvas). Genotyping was performed in 197 of 198 patients with nephropathy and 191 Results (4G/5G) and 192 (ApoE ) patients in the normoalbuminuric group. Subjects were classified into one of three PAI-1 The group of patients with nephropathy and the norgenotype groups: 4G4G, 4G5G or 5G5G and one of six moalbuminuric group were well matched with regard ApoE genotypes: e2/e2, e2/e3, e2/e4, e3/e3, e3/e4 or e4/e4. to sex, age and duration of diabetes. Clinical data from Patients with the e2/e4 genotype (n=10) were excluded from these patients are shown in Table 1. the analyses comparing ApoE allele carriers.
Patients with nephropathy had elevated systolic and Plasma PAI-1 antigen was determined for all samples in a diastolic blood pressure and raised serum creatinine single assay run, using the Thrombonostika PAI-1 ELISA kit (Organon Teknika, Turnhout, Belgium). In parallel assays and HbA 1c
, in addition to increased serum cholesterol (n=11) using pooled normal plasma, the intra-assay coeffi-and triglycerides compared with patients with normoalcient of variation was 6.8%.
buminuria (P<0.001).
Patients were interviewed using the World Health Nephropathic patients had a higher prevalence of Organization ( WHO) cardiovascular questionnaire [29] . A proliferative retinopathy [137 (69%)] compared with 12-lead electrocardiogram ( ECG) was recorded and sub-the normoalbuminuric group [18 (10%)] (P<0.001).
sequently coded independently by two trained observers, Male patients with diabetic nephropathy had who were blinded to the clinical status of the patients, using elevated plasma PAI-1 levels, 70 (62-79) ng/ml Minnesota Rating Scale [30] . CHD was diagnosed if the compared with normoalbuminuric men, 43 (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) ECG showed signs of probable myocardial infarction ng/ml, P<0.001. PAI-1 levels were similarly elevated (Minnesota Rating Scale 1.1-2) or possible myocardial ischaemia (Minnesota Rating Scale 1.3, 4.1-4, 5.1-3 or 7.1), in nephropathic men with duration of persistent Mean±SD, amedian (range). bSome patients with previously persistent albuminuria receiving antihypertensive medication had an urinary albumin excretion rate<300 mg/24 h at the time of investigation.
proteinuria above and below the median value of 8 with the 4G5G genotype was smaller (n=80) than expected (n=95), P=0.03. The distribution of ApoE years, 63 (52-76) vs 75 (64-87) ng/ml, n.s. Within the nephropathic group, no difference in plasma PAI-1 genotypes overall, as in cases and controls separately, did not differ from Hardy-Weinberg equilibrium (n.s.). was seen when data were dichotomized according to median serum creatinine, nor did PAI-1 levels differ
The prevalence of CHD was elevated in patients with nephropathy, 19 (16) (17) (18) (19) (20) (21) (22) % vs 8 (4-12)% in norbetween sexes or between patients who were or were not receiving antihypertensive medication or aspirin at moalbuminuric patients, P<0.001. Among patients with nephropathy, those suffering from CHD were the time of examination (n.s.). In women no significant difference in plasma PAI-1 levels was observed between older 45.1±9.7 vs 40.0±9.3 years (P<0.005) and had a longer duration of diabetes 29.3±8.9 vs 26.1±7.6 patients with and without nephropathy: 66 (57-76) vs 56 (50-64) ng/ml, respectively. years (P=0.02). In addition, systolic blood pressure and serum creatinine were elevated: 160±23 vs There was a borderline significant difference in plasma PAI-1 levels between PAI-1 genotypes in the 150±22 mmHg (P<0.01) and 127 (73-684) vs 96 (54-403) mmol/l (P<0.001), respectively. The majority group of patients with nephropathy (P=0.05), in which patients with the 4G4G genotype tended to have a [95 (88-100)%] of nephropathic patients with CHD received antihypertensive medication, compared with higher concentration of PAI-1 in plasma 79 (65-96) ng/ml, than in patients carrying the 5G allele 72 (65-79)% of nephropathic patients without CHD, P<0.005. In the nephropathic group, serum choles-65 (58-72) ng/ml, P=0.06. No relationship between PAI-1 genotypes and plasma PAI-1 levels was detected terol (P=0.02) and triglycerides (P=0.01) were raised in patients with CHD: 6.1±1.4 and 1.44 (0.74-5.07) in the normoalbuminuric group. There was no difference in the regression slopes of PAI-1 levels on serum vs 5.5±1.2 and 1.19 (0.31-9.87) mmol/l in patients without CHD. Sex distribution was similar and BMI, triglycerides between genotype groups (n.s.). Serum cholesterol, LDL-cholesterol and ApoB levels were HbA 1c , urinary albumin excretion rate, diastolic blood pressure and serum HDL-cholesterol did not differ higher in nephropathic patients with the e4-allele, whereas HDL-cholesterol and triglycerides did not between nephropathic patients with and without CHD.
No relationship between plasma PAI-1 and the presdiffer significantly between carriers of ApoE e2-alleles, e3-alleles and e4-alleles ( Table 2) .
ence/absence of CHD was seen in the group of patients with nephropathy (data not shown). Furthermore, the Table 3 shows that no difference in PAI-1 genotype distribution was observed between type 1 diabetic distribution of PAI-1 genotypes was similar in nephropathic patients with vs without CHD: 7, 24 and 7 vs patients with diabetic nephropathy and those with normoalbuminuria. Furthermore, no difference in 47, 80 and 32 patients had 4G4G, 4G5G and 5G5G genotypes respectively, n.s. In contrast, a significant ApoE genotype distribution, allele frequency or allele carrier status was observed between patients with and association existed between the ApoE polymorphism and CHD (chi-square=17.96, 2 df: P<0.001) the frewithout nephropathy ( Table 3 ). The distributions of PAI-1 and ApoE genotypes were similar in men and quency of the e4-allele being higher among type 1 diabetic patients with diabetic nephropathy and CHD, women, n.s.
Overall the distribution of PAI-1 genotypes did not 0.303 vs 0.116 in nephropathic patients without CHD, P<0.001. Accordingly, 36% (17/47) of nephropathic differ from Hardy-Weinberg equilibrium (n.s.), whereas in the normoalbuminuric group, the number of patients patients carrying the e4-allele had CHD, whereas only help to explain the lack of association between this macrovascular complication and plasma PAI-1 concenData are given as numbers (%).
tration seen in the present study. Suppression of plasma PAI-1 due to ACE inhibition has been suggested in clinical studies [37, 38] , and because most of the 12% (13/112) of patients with the wild-type e3/e3 nephropathic patients with CHD were treated with genotype showed signs of CHD, P<0.001.
ACE inhibitors, such an effect would confound the Finally, no differences in PAI-1 levels or PAI-1 and association between PAI-1 and CHD. ApoE genotype distributions were seen between Some [9,11], but not all [13] , studies of non-diabetic patients with proliferative retinopathy, simplex or no populations have found an association between the diabetic retinopathy in either the nephropathic or the 4G4G genotype of a polymorphism in the promoter normoalbuminuric group (data not shown).
region of the PAI-1 gene and elevated plasma PAI-1 activity. In two studies of type 2 diabetic Pima Indians Discussion no relationship between promoter genotype and plasma PAI-1 activity was found [14, 15] . In the present study of type 1 diabetic patients with diabetic nephroOur case-control study revealed no associations pathy, a weak association existed between plasma between the PAI-1 (4G/5G) or the ApoE polymorph-PAI-1 concentrations and promoter genotype, with the ism and diabetic nephropathy or retinopathy in highest values being found in patients with the 4G4G Caucasian type 1 diabetic patients. The atherogenic genotype. In the normoalbuminuric group, with lower e4-allele was seen more frequently in patients with PAI-1 concentrations, no differences between geno-CHD and diabetic nephropathy, a condition characterized by elevated plasma PAI-1 in men.
types were detected. Assuming a gene-environment interaction between PAI-1 genotype and plasma glu-macroalbuminuria was found in that study [40] . These results are in contrast to a recent study from the UK, cose, as suggested by Mansfield et al. [39] , the poorer metabolic control in patients with nephropathy in the in which the authors reported an excess of the e2-allele in type 1 diabetic patients with nephropathy compared present study might help to explain the observed differences between groups.
with a group of type 1 diabetic patients with normoor microalbuminuria [41] . By including patients with The lack of an association between the PAI-1 (4G/5G) polymorphism and diabetic nephropathy in microalbuminuria among the controls, this design harbours a substantial risk for misclassification of patients, our Caucasian type 1 diabetic patients is in accordance with data from a cross-sectional study of type 2 diabetic who will subsequently progress to overt diabetic nephropathy, despite long-standing diabetes [42] . Pima Indians [15] . Furthermore, our cohorts were sufficiently large to yield 98% power to detect a 20%
In accordance with a previous study in type 2 diabetes [25] , our study of type 1 diabetic patients deviation in 4G4G genotype frequency, with P<0.05. Our negative finding is thus not explained by insuffi-demonstrated an increased prevalence of CHD in nephropathic patients carrying the e4-allele. cient statistical power.
Plasma PAI-1 levels were not elevated in patients Population stratification, selection, methodological problems and chance might result in a deviation from with retinopathy in either the present or a previous study [15] . Whereas simplex retinopathy was more the Hardy-Weinberg equilibrium. In this study, patients for the cardiovascular low-risk normoalbuminuric conpredominant in carriers of the 4G allele in a study of Pima Indians [15] , no association between PAI-1 gene trol group were recruited from the same homogenous Danish diabetic population as cases. Furthermore, polymorphisms and retinopathy was found in Caucasian patients (this study; Ref. 19 ). Discrepancies applied methods to determine genotypes are validated, and only one other gene polymorphism investigated between studies can be ascribed to different phenotypes, i.e. type of diabetes, severity of retinopathy [26 ] has been in Hardy-Weinberg disequilibrium in this normoalbuminuric group. Therefore, we consider and/or ethnical differences, and finally the possibility of chance findings-positive or negative. Future the observed deviation in PAI-1 genotype in controls to be a chance finding. investigation of this topic in studies designed to investigate the genetics of diabetic retinopathy will be
In conclusion, the ApoE polymorphism may accelerate the development of CHD often seen in Caucasian required.
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